Life Sciences Market Research Report
Report Filter Reset All
Sort By Price
Published Date
Category
Publishers
Report Type
Continents
Regions
Global Midostaurin Market Insights, Forecast to 2025
Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndro...
$3,900.00 22 May, 2019 | QYResearch
Global Midostaurin Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplas...
Global Midostaurin Drugs Market Insights, Forecast to 2025
Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndro...
$3,900.00 22 May, 2019 | QYResearch
Global Midostaurin Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Midostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplas...
Global Ivosidenib Market Insights, Forecast to 2025
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global...
$3,900.00 22 May, 2019 | QYResearch
Global Ivosidenib Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. ...
Global Ivosidenib Drugs Market Insights, Forecast to 2025
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global...
$3,900.00 22 May, 2019 | QYResearch
Global Ivosidenib Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. ...
Global Tibsovo Market Insights, Forecast to 2025
Tibsovo is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Ti...
$3,900.00 22 May, 2019 | QYResearch
Global Tibsovo Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Tibsovo is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The...
Global Cytarabine and Daunorubicin Market Insights, Forecast to 2025
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin market is...
$3,900.00 22 May, 2019 | QYResearch
Global Cytarabine and Daunorubicin Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin...
Global Cytarabine and Daunorubicin Drugs Market Insights, Forecast to 2025
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin Drugs mar...
$3,900.00 22 May, 2019 | QYResearch
Global Cytarabine and Daunorubicin Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin...
Global Vyxeos Market Insights, Forecast to 2025
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Vyxeos market is valued at xx million...
$3,900.00 22 May, 2019 | QYResearch
Global Vyxeos Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Vyxeos market is valued at ...
Global Acute Myeloid Leukemia Drugs Market Insights, Forecast to 2025
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 1...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Myeloid Leukemia Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from ...
Global Trisenox Market Insights, Forecast to 2025
Trisenox is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocytic leukae...
$3,900.00 22 May, 2019 | QYResearch
Global Trisenox Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Trisenox is a chemotherapy drug and is also called Trisenox or ATO. It is a treatment for a type of acute myeloid leukaemia called acute promyelocy...
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
